TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7037487
Drug: Metergoline (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metergoline (10 mg daily for two days plus a 4 mg dose 1 hour before the post-treatment test)
Study: 30361325
Drug: Sparsentan (200,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sparsentan (200, 400, or 800 mg/d)
Study: 30361325
Drug: Sparsentan (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sparsentan (400 and 800 mg/d)
Study: 24811201
Drug: Nicotine patch
Normalized name: Nicotine Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patch (n=182)
Study: 24811201
Drug: Placebo patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo patch (n=180)
Study: 21062541
Drug: Psychologically informed
Normalized name: INFORMATION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychologically informed sessions based on cognitive-behavioural therapy or person-centred counselling principles
Study: 2851181
Drug: Cisplatin 120
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 120 mg/m2 every 4 weeks and vindesine 3 mg/m2 weekly
Study: 2851181
Drug: Cisplatin/vindesine (chemotherapy)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin/vindesine (chemotherapy)
Study: 31993658
Drug: Distress Tolerance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Distress Tolerance Treatment (DT-W)
Study: 27030088
Drug: Liothyronine 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liothyronine 15 μg for two weeks, then 30-45 μg for four weeks
Study: 27030088
Drug: Liothyronine 30-45
Normalized name: LEVOTHYROXINE NA 180MCG/LIOTHYRONINE NA 45MCG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liothyronine 30-45 μg
Study: 27030088
Drug: Liothyronine therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liothyronine therapy
Study: 15961567
Drug: Early headgear
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early headgear (HG) treatment initiated immediately
Study: 15961567
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups underwent orthodontic therapy including fixed appliances and possible extractions when necessary
Study: 10233492
Drug: L-arginine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (5 g/day)
Study: 1760424
Drug: Norethisterone acetate
Normalized name: Norethisterone acetate
DrugBank: Norethisterone (DB00717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norethisterone acetate (NEA) 1 mg + ethinyl oestradiol (EE) 50 micrograms
Study: 30981629
Drug: Intravenous ferric
Normalized name: Ferric Oxide
DrugBank: Ferric oxide (DB11576)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ferric carboxymaltose (1000 mg, n = 86)
Study: 30981629
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron (II) fumarate (100 tablets of 100 mg [10 per week], n = 90)
Study: 19172098
Drug: Sildenafil (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (50 mg) twice a week for 4 months
Study: 19172098
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (10 patients with ED who did not take any treatment)
Study: 15710092
Drug: Gabapentin (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (up to 3,600 mg/day)
Study: 12213867
Drug: Nateglinide 30
Normalized name: nateglinide 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nateglinide 30 mg
Study: 12213867
Drug: Nateglinide (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nateglinide (all doses)
Study: 3781675
Drug: Propranolol, 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol, 40 mg t.i.d.
Study: 3781675
Drug: Diltiazem, 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem, 60 mg t.i.d.
Study: 24237386
Drug: Dapagliflozin 5
Normalized name: dapagliflozin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin 5 mg once daily for 12 weeks
Study: 22726914
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral smoking cessation treatment (CBT)
Study: 24446953
Drug: BRV 5
Normalized name: Brivaracetam
DrugBank: Brivaracetam (DB05541)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: BRV 5 mg/day
Study: 24446953
Drug: BRV 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: BRV 20 mg/day
Study: 18824852
Drug: Intermittent pantoprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent pantoprazole infusion
Study: 18824852
Drug: Continuous pantoprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous pantoprazole infusion
Study: 8458598
Drug: L-Dopa (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-Dopa (300 mg total: 50 mg at 9 am, 100 mg before lunch, 150 mg before dinner)
Study: 3752422
Drug: 0.03 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.03 mg/kg lormetazepam
Study: 3752422
Drug: 0.02 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.02 mg/kg flunitrazepam
Study: 30666823
Drug: Belimumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Belimumab (10 mg/kg) plus azathioprine (2 mg/kg/day) and low-dose oral glucocorticoids (≤10 mg/day)
Study: 30666823
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus azathioprine (2 mg/kg/day) and low-dose oral glucocorticoids (≤10 mg/day)
Study: 30666823
Drug: Belimumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Belimumab (10 mg/kg)
Study: 30020423
Drug: S-ketamine (0.006
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-ketamine (0.006 mg/kg/min)
Study: 22168398
Drug: 0 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg bupropion
Study: 22168398
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg bupropion
Study: 22168398
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg bupropion
Study: 19187813
Drug: Residential Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Residential Cognitive Therapy (RCT)
Study: 18846473
Drug: Residential Interpersonal
Normalized name: ALUMINUM CHLOROHYDRATE 200 mg in 1 mL TOPICAL LIQUID [PRESIDENTIAL LEATHER]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Residential Interpersonal Therapy (RIPT)
Study: 15315717
Drug: Fluoxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (20 mg, single oral dose)
Study: 15315717
Drug: Fluoxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (20 mg/d, repeated dosing for 2 weeks)
Study: 11449834
Drug: Multidisciplinary pain
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidisciplinary pain treatment (MPT)
Study: 10399516
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg hyperbaric bupivacaine plus 25 micrograms fentanyl (0.5 ml) and cerebrospinal fluid (CSF) 0.6 ml (Group M + F)
Study: 10399516
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg hyperbaric bupivacaine plus 0.5 ml of CSF (Group M)
Study: 8002551
Drug: Overtraining group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overtraining group (OT); weight trained legs daily for 2 weeks with 100% 1 repetition maximum
Study: 3244794
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg PLG i.v.
Study: 27477844
Drug: GMZ2 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GMZ2 vaccine (100μg adjuvanted with aluminum hydroxide)
Study: 27477844
Drug: Control vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control vaccine (rabies)
Study: 27477844
Drug: GMZ2 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GMZ2 vaccine
Study: 23698199
Drug: 0.2% levobupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% levobupivacaine with 2 Mi g/ml fentanyl
Study: 23698199
Drug: 0.1% levobupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% levobupivacaine with 2 Mi g/ml fentanyl
Study: 20861739
Drug: ramelteon (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: ramelteon (8 mg/day)
Study: 9892876
Drug: pumaprazole (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: pumaprazole (100 mg b.d.)
Study: 9892876
Drug: omeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: omeprazole (20 mg o.d.)
Study: 26536019
Drug: Memantine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine (10 mg/day initially and 20 mg/day at the end of the first week)
Study: 23314272
Drug: Peptide/CAF01 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peptide/CAF01 vaccine
Study: 21980373
Drug: Single-dose mebendazole
Normalized name: Mebendazole
DrugBank: Mebendazole (DB00643)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose mebendazole (500 mg)
Study: 21980373
Drug: Triple-dose albendazole
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triple-dose albendazole (3×400 mg over 3 consecutive days)
Study: 21980373
Drug: Triple-dose mebendazole
Normalized name: Mebendazole
DrugBank: Mebendazole (DB00643)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triple-dose mebendazole (3×500 mg over 3 consecutive days)
Study: 21980373
Drug: Triple-dose mebendazole
Normalized name: Mebendazole
DrugBank: Mebendazole (DB00643)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triple-dose mebendazole
Study: 21980373
Drug: Single and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single and triple doses of either drug
Study: 21980373
Drug: Triple-dose regimens
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple-dose regimens
Study: 2138925
Drug: Single-dose regimens
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose regimens
Study: 19570098
Drug: Oral dietary
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral dietary supplement containing antioxidants, minerals and glycosaminoglycans
Study: 18162024
Drug: Duloxetine 30
Normalized name: duloxetine 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 30 mg q.a.m.
Study: 18162024
Drug: Duloxetine 60
Normalized name: duloxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 60 mg q.a.m.
Study: 18162024
Drug: Duloxetine 30
Normalized name: duloxetine 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 30 mg b.i.d.
Study: 18162024
Drug: Duloxetine 30
Normalized name: duloxetine 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 30 mg q.a.m. (with food)
Study: 18162024
Drug: Duloxetine 30
Normalized name: duloxetine 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 30 mg b.i.d. (with food)
Study: 18162024
Drug: Duloxetine 60
Normalized name: duloxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 60 mg q.a.m. (with food)
Study: 18162024
Drug: Duloxetine 30
Normalized name: duloxetine 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 30 mg q.a.m. without food
Study: 18162024
Drug: Duloxetine 30
Normalized name: duloxetine 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 30 mg b.i.d. without food
Study: 18162024
Drug: Duloxetine 60
Normalized name: duloxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 60 mg q.a.m. without food
Study: 15181401
Drug: Sevoflurane administration
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevoflurane administration for 15 min before coronary occlusion
Study: 15181401
Drug: No sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No sevoflurane administration (Control group)
Study: 24486335
Drug: Intravenous ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ondansetron 4 mg
Study: 3434165
Drug: No local
Approvals — FDA: no, EMA: no, PMDA: no
Description: No local treatment
Study: 28400446
Drug: Avacopan (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avacopan (30 mg, twice daily) plus reduced-dose prednisone (20 mg daily)
Study: 28400446
Drug: Avacopan (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avacopan (30 mg, twice daily) without prednisone
Study: 28400446
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus prednisone (60 mg daily)
Study: 25043459
Drug: Teriparatide 20 µg
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Teriparatide 20 µg daily
Study: 25043459
Drug: Denosumab 60 mg
Normalized name: Denosumab
DrugBank: Denosumab (DB06643)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Denosumab 60 mg every 6 months
Study: 23549780
Drug: quasi-volumetric modulated
Approvals — FDA: no, EMA: no, PMDA: no
Description: quasi-volumetric modulated arc therapy (qVMAT)
Study: 23549780
Drug: intensity-modulated radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intensity-modulated radiation therapy (IMRT)
Study: 23549780
Drug: 3D-conformal radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3D-conformal radiation therapy (3D-CRT)
Study: 10666534
Drug: Vibration therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vibration therapy (60 Hz frequency, 45-min treatment)
Study: 10666534
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment (audible hum and lit control box without vibration)
Study: 10666534
Drug: Vibration therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vibration therapy vs. Sham treatment
Study: 9327190
Drug: etodolac 200
Normalized name: etodolac 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: etodolac 200 mg
Study: 9327190
Drug: acetaminophen plus
Normalized name: acetaminophen / hydrocodone Oral Capsule [Ceta Plus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: acetaminophen plus codeine (Tylenol #3)
Study: 8380310
Drug: Estrogen pretreatment
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen pretreatment (2.5 mg of conjugated estrogen, Premarin)
Study: 3533271
Drug: L-5-hydroxytryptophan (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-5-hydroxytryptophan (5 mg/kg body weight)
Study: 28881387
Drug: Lactoferrin (LF)
DrugBank: Lactoferrin (DB16555)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactoferrin (LF) and lactoperoxidase (LPO) containing tablets
Study: 25987323
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (MPH) treatment during double-blind trials and a 6-month open-label phase
Study: 9284855
Drug: Low-dose dopamine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose dopamine (4 micrograms/kg/min) + low-dose furosemide (80 mg/day)
Study: 9284855
Drug: Low-dose dopamine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose dopamine (4 micrograms/kg/min) + medium-dose furosemide (5 mg/kg/day)
Study: 9284855
Drug: High-dose furosemide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose furosemide (10 mg/kg/day)
Study: 18075922
Drug: Brief intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief intervention package for hazardous drinkers; details on dosage and duration not specified.
Study: 15077240
Drug: Zydis selegiline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zydis selegiline 1.25 mg
Study: 15077240
Drug: Zydis selegiline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zydis selegiline 2.5 mg
Study: 10214571
Drug: ADCON‐L
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADCON‐L
Study: 7251221
Drug: Adjuvant tamoxifen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant tamoxifen treatment (20 mg twice daily for 2 years)
Study: 7251221
Drug: Postoperative adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative adjuvant radiotherapy or chemotherapy
Study: 23328162
Drug: Naftopidil (Naf)
Normalized name: Naftopidil
DrugBank: Naftopidil (DB12092)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Naftopidil (Naf) 50-75 mg once daily for 2 weeks followed by 75 mg once daily for 4 weeks
Study: 23328162
Drug: Silodosin (Silo)
Normalized name: Silodosin
DrugBank: Silodosin (DB06207)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Silodosin (Silo) 2-4 mg twice daily for 2 weeks followed by 4 mg twice daily for 4 weeks
Study: 15469803
Drug: Oral deflazacort
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral deflazacort (1.5 mg/kg) for 7 days
Study: 15469803
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone (1 mg/kg) for 7 days
Study: 10399518
Drug: Epidural block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural block (caudal) with 11-15 ml of 2% lidocaine
Study: 30362137
Drug: Extra-short implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extra-short implants (≤6 mm)
Study: 30362137
Drug: Long implants
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long implants (≥10 mm)
Study: 29349999
Drug: Epidural injection
Normalized name: Sufentanil Citrate 50 ug in 1 mL EPIDURAL INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural injection of Diprospan, Lidocaine, and Mecobalamine after PELD
Study: 29349999
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline injection after PELD
Study: 29349999
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (PELD with and without epidural injection)
Study: 23702610
Drug: Ahmed valve
Normalized name: VALVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ahmed valve implant surgery with combined short scleral tunnel with Tenon advancement and duplication technique
Study: 23702610
Drug: AGV implant
Normalized name: petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AGV implant surgery without patch graft
Study: 23702610
Drug: AGV implant
Normalized name: petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AGV implant surgery with donor scleral patch
Study: 21388309
Drug: Olmesartan (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan (40 mg once daily)
Study: 19930508
Drug: Repeated testing
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated testing (SE-T/MG-S group)
Study: 19930508
Drug: Repeated study
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated study (MG-T/SE-S group)
Study: 9260068
Drug: Ethanol (0.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (0.5, 1.0, and 2.0 g/kg)
Study: 9260068
Drug: Pentobarbital (150,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentobarbital (150, 300, 600, and 750 mg/70 kg)
Study: 2545773
Drug: Oral dextroamphetamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dextroamphetamine 20 mg
Study: 81190
Drug: Regimen B
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen B (BACON combination, slightly modified)
Study: 28452960
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg per day Pycnogenol® (P+)
Study: 28452960
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (Co)
Study: 24306695
Drug: 1.0 mg/mL
Normalized name: P.T.E.-4, 1 mcg-0.1 mg-0.025 mg-1.0 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg/mL rhBMP-2/CPM
Study: 24306695
Drug: 2.0 mg/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 mg/mL rhBMP-2/CPM
Study: 17099012
Drug: Zolpidem (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem (oral hypnotic agent)
Study: 8907804
Drug: Indobufen [200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indobufen [200 mg orally twice daily (p.o. b.i.d.) for a week]
Study: 1685875
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg lormetazepam alone
Study: 1685875
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg lormetazepam with 200 mg cimetidine
Study: 25402429
Drug: 2% M.
Normalized name: Methylcellulose 2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% M. hamburg grape seed extract formulation
Study: 17634482
Drug: AZD2171 (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD2171 (0.5 to 60 mg, once-daily)
Study: 17634482
Drug: AZD2171 (20,
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD2171 (20, 30, or 45 mg, once-daily)
Study: 17634482
Drug: AZD2171 (once-daily)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD2171 (once-daily)
Study: 7535040
Drug: High-dose aprotinin
Normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose aprotinin (6 x 10(6) KIU) (Group B)
Study: 30472123
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg IV ibuprofen in 100 mL saline
Study: 28225506
Drug: 100 mL
Normalized name: PVC IV Bag 100 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mL saline solution
Study: 28283286
Drug: Prophylactic platelet
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic platelet transfusion plus supportive care (4 units of pooled platelets given daily when platelet count was 20,000 per μL or lower)
Study: 19623149
Drug: L‐adrenaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐adrenaline
Study: 11599649
Drug: 90-mg weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90-mg weekly enteric-coated fluoxetine
Study: 11599649
Drug: 20-mg daily
Normalized name: glecaprevir
DrugBank: Glecaprevir (DB13879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 20-mg daily fluoxetine
Study: 2831788
Drug: Enalapril (10‐20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (10‐20 mg) with hydrochlorothiazide plus amiloride
Study: 2831788
Drug: Timolol (10‐20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol (10‐20 mg) with hydrochlorothiazide plus amiloride
Study: 15016559
Drug: Bimatoprost 0.03%
Normalized name: BIMATOPROST 0.03% SOLN,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bimatoprost 0.03% ophthalmic solution QD (n=38)
Study: 15016559
Drug: Latanoprost 0.005%
Normalized name: LATANOPROST 0.005% SOLN,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Latanoprost 0.005% ophthalmic solution QD (n=38)